Holen Sie sich die Stockscreener-App
5.30
11.34%
0.54
Handel nachbörslich:
5.30
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Robert W. Baird to Outperform Rating - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance
Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Q3 2024 Financial Highlights - TipRanks
Amylyx Pharmaceuticals Inc. (AMLX) Quarterly 10-Q Report - Quartz
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class A - GuruFocus.com
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 21.1% - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Yahoo Finance
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharma - GuruFocus.com
Amylyx upgraded to buy by BofA on hypoglycemia drug potential - MSN
BofA upgrades Amylyx stock to Buy rating By Investing.com - Investing.com Australia
BofA upgrades Amylyx stock to Buy rating - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Buy by Bank of America - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com
October 2024's US Penny Stocks Poised For Growth - Simply Wall St
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial - MSN
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Insider Monkey
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - MSN
Amylyx shares reiterate Buy rating on trial data - Investing.com
Amylyx shares reiterate Buy rating on trial data By Investing.com - Investing.com UK
Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data - Investing.com
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data By Investing.com - Investing.com UK
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Clinical Trials Arena
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance
Leerink maintains Market Perform rating on Amylyx stock on new data - Investing.com
Leerink maintains Market Perform rating on Amylyx stock on new data By Investing.com - Investing.com South Africa
Amylyx reports positive trial results for Wolfram syndrome treatment - Investing.com India
Amylyx reports positive trial results for Wolfram syndrome treatment By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - StockTitan
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - BioSpace
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Millennium Management LLC - MarketBeat
Deutsche Bank Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Target Price at $17.60 - MarketBeat
American Century Companies Inc. Reduces Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):